Improving lithium therapeutics by crystal engineering of novel ionic cocrystals

Molecular Pharmaceutics

Volumn 10, Issue 12, 2013, Pages 4728-4738

  Smith, Adam J ^a   Kim, Seol Hee ^a   Duggirala, Naga K ^b   Jin, Jingji ^a   Wojtas, Lukasz ^b   Ehrhart, Jared ^a   Giunta, Brian ^a   Tan, Jun ^a   Zaworotko, Michael J ^b   Shytle, R Douglas ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

bipolar disorder; cocrystals; gsk 3; lithium; pharmacokinetics

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LITHIUM; LITHIUM CARBONATE; LITHIUM DERIVATIVE; LITHIUM SALICYLATE PROLINE; LITHIUM SALT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CRYSTAL; CRYSTAL STRUCTURE; DENSITOMETRY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HYDROGEN BOND; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MALE; MICROGLIA; NEURAL STEM CELL; NEUROBLASTOMA CELL; NONHUMAN; PHARMACEUTICAL ENGINEERING; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; IONS; LITHIUM; MICE; MICROGLIA; NEURAL STEM CELLS; NITRIC OXIDE; PHOSPHORYLATION; RATS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84889241646     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400571a     Document Type: Article

References (69)

1. Shorter, E. The history of lithium therapy Bipolar Disord. 2009, 11 (Suppl 2) 4-9
2. Thies-Flechtner, K.; Muller-Oerlinghausen, B.; Seibert, W.; Walther, A.; Greil, W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial Pharmacopsychiatry 1996, 29 (3) 103-107
3. Goodwin, F. K.; Fireman, B.; Simon, G. E.; Hunkeler, E. M.; Lee, J.; Revicki, D. Suicide risk in bipolar disorder during treatment with lithium and divalproex JAMA 2003, 290 (11) 1467-1473 (Pubitemid 37430401)
4. Cipriani, A.; Hawton, K.; Stockton, S.; Geddes, J. R. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis BMJ 2013, 346, f3646
5. Davenport, V. D. Distribution of parenterally administered lithium in plasma, brain and muscle of rats Am. J. Physiol. 1950, 163 (3) 633-641
6. Ebadi, M. S.; Simmons, V. J.; Hendrickson, M. J.; Lacy, P. S. Pharmacokinetics of lithium and its regional distribution in rat brain Eur. J. Pharmacol. 1974, 27 (3) 324-329
7. Livingstone, C.; Rampes, H. Lithium: a review of its metabolic adverse effects J. Psychopharmacol. 2006, 20 (3) 347-355
8. Schou, M.; Baastrup, P. C.; Grof, P.; Weis, P.; Angst, J. Pharmacological and clinical problems of lithium prophylaxis Br. J. Psychiatry 1970, 116 (535) 615-619
9. Fukumoto, T.; Morinobu, S.; Okamoto, Y.; Kagaya, A.; Yamawaki, S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain Psychopharmacology 2001, 158 (1) 100-106
10. Leyhe, T.; Eschweiler, G. W.; Stransky, E.; Gasser, T.; Annas, P.; Basun, H.; Laske, C. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease J. Alzheimer's Dis. 2009, 16 (3) 649-656
11. Yuskaitis, C. J.; Jope, R. S. Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity Cell. Signalling 2009, 21 (2) 264-273
12. Frick, L. R.; Williams, K.; Pittenger, C. Microglial dysregulation in psychiatric disease Clin. Dev. Immunol. 2013, 2013, 608654
13. Ricken, R.; Adli, M.; Lange, C.; Krusche, E.; Stamm, T. J.; Gaus, S.; Koehler, S.; Nase, S.; Bschor, T.; Richter, C.; Steinacher, B.; Heinz, A.; Rapp, M. A.; Borgwardt, S.; Hellweg, R.; Lang, U. E. Brain-Derived Neurotrophic Factor Serum Concentrations in Acute Depressive Patients Increase During Lithium Augmentation of Antidepressants J. Clin. Psychopharmacol. 2013, 33 (6) 806-809
14. Ghasemi, M.; Sadeghipour, H.; Mosleh, A.; Sadeghipour, H. R.; Mani, A. R.; Dehpour, A. R. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test Eur. Neuropsychopharmacol. 2008, 18 (5) 323-332 (Pubitemid 351381351)
15. Phiel, C. J.; Klein, P. S. Molecular targets of lithium action Annu. Rev. Pharmacol. Toxicol. 2001, 41, 789-813 (Pubitemid 32385907)
16. Klein, P. S.; Melton, D. A. A molecular mechanism for the effect of lithium on development Proc. Natl. Acad. Sci. U.S.A. 1996, 93 (16) 8455-8459 (Pubitemid 26269579)
17. Alon, L. T.; Pietrokovski, S.; Barkan, S.; Avrahami, L.; Kaidanovich-Beilin, O.; Woodgett, J. R.; Barnea, A.; Eldar-Finkelman, H. Selective loss of glycogen synthase kinase-3alpha in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation FEBS Lett. 2011, 585 (8) 1158-1162
18. Rowe, M. K.; Wiest, C.; Chuang, D. M. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder Neurosci. Biobehav. Rev. 2007, 31 (6) 920-931 (Pubitemid 47285347)
19. Yao, H. B.; Shaw, P. C.; Wong, C. C.; Wan, D. C. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain J. Chem. Neuroanat. 2002, 23 (4) 291-297 (Pubitemid 34606866)
20. Avila, J.; Hernandez, F. GSK-3 inhibitors for Alzheimer's disease Expert Rev. Neurother. 2007, 7 (11) 1527-1533 (Pubitemid 350106832)
21. Dewhurst, S.; Maggirwar, S. B.; Schifitto, G.; Gendelman, H. E.; Gelbard, H. A. Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS J. Neuroimmune Pharmacol. 2007, 2 (1) 93-96
22. Yuskaitis, C. J.; Mines, M. A.; King, M. K.; Sweatt, J. D.; Miller, C. A.; Jope, R. S. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome Biochem. Pharmacol. 2010, 79 (4) 632-646
23. Allison, J. H.; Stewart, M. A. Reduced brain inositol in lithium-treated rats Nature (London), New Biol. 1971, 233 (43) 267-268
24. Pollack, S. J.; Atack, J. R.; Knowles, M. R.; McAllister, G.; Ragan, C. I.; Baker, R.; Fletcher, S. R.; Iversen, L. L.; Broughton, H. B. Mechanism of inositol monophosphatase, the putative target of lithium therapy Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (13) 5766-5770 (Pubitemid 24188222)
25. Harwood, A. J. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited Mol. Psychiatry 2005, 10 (1) 117-126 (Pubitemid 40139592)
26. Singh, N.; Halliday, A. C.; Thomas, J. M.; Kuznetsova, O. V.; Baldwin, R.; Woon, E. C.; Aley, P. K.; Antoniadou, I.; Sharp, T.; Vasudevan, S. R.; Churchill, G. C. A safe lithium mimetic for bipolar disorder Nature Commun. 2013, 4, 1332
27. Goodwin, F. K.; Jamison, K. R. Manic-depressive illness; Oxford University Press: New York, 1990; pp xxi, 938
28. Kilbane, E. J.; Gokbayrak, N. S.; Galynker, I.; Cohen, L.; Tross, S. A review of panic and suicide in bipolar disorder: does comorbidity increase risk? J. Affective Disord. 2009, 115 (1-2) 1-10
29. U.S. Food and Drug Administration. Guidance for Industry: Regulatory Classification of Pharmaceutical Co-Crystals; U.S. Food and Drug Administration: Silver Spring, MD, 2013
30. Almarsson, O.; Zaworotko, M. J. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chemical Commun. 2004, 17, 1889-1896 (Pubitemid 39335992)
31. Desiraju, G. R. Supramolecular Synthons in Crystal Engineering-A New Organic Synthesis Angew. Chem. 1995, 34 (21) 2311-2327
32. Moulton, B.; Zaworotko, M. J. From molecules to crystal engineering: supramolecular isomerism and polymorphism in network solids Chem. Rev. 2001, 101 (6) 1629-1658 (Pubitemid 35377799)
33. Almarsson, Ö.; Peterson, M. L.; Zaworotko, M. The A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents Pharm. Pat. Anal. 2012, 1 (3) 313-327
34. Smith, A. J.; Kavuru, P.; Wojtas, L.; Zaworotko, M. J.; Shytle, R. D. Cocrystals of quercetin with improved solubility and oral bioavailability Mol. Pharmaceutics 2011, 8 (5) 1867-1876
35. Smith, A. J.; Kavuru, P.; Arora, K. K.; Kesani, S.; Tan, J.; Zaworotko, M. J.; Shytle, R. D. Crystal engineering of green tea epigallocatechin-3-gallate (EGCg) cocrystals and pharmacokinetic modulation in rats Mol. Pharmaceutics 2013, 10 (8) 2948-2961
36. Wouters, J.; Grepioni, F.; Braga, D.; Kaminski, R. M.; Rome, S.; Aerts, L.; Quere, L. Novel Pharmaceutical Compositions through Co-crystallization of Racetams and Li+ Salts CrystEngComm 2013, 15, 8898-8902
37. Chierotti, M. R.; Gaglioti, K.; Gobetto, R.; Braga, D.; Grepioni, F.; Maini, L. From molecular crystals to salt co-crystals of barbituric acid via the carbonate ion and an improvement of the solid state properties CrystEngComm 2013, 15, 7598-7605
38. Braga, D.; Grepioni, F.; Maini, L.; Capucci, D.; Nanna, S.; Wouters, J.; Aerts, L.; Quere, L. Combining piracetam and lithium salts: ionic co-crystals and co-drugs? Chem. Commun. 2012, 48 (66) 8219-8221
39. Ong, T. T.; Kavuru, P.; Nguyen, T.; Cantwell, R.; Wojtas, L.; Zaworotko, M. J. 2:1 cocrystals of homochiral and achiral amino acid zwitterions with Li+ salts: water-stable zeolitic and diamondoid metal-organic materials J. Am. Chem. Soc. 2011, 133 (24) 9224-9227
40. Braga, D.; Grepioni, F.; Maini, L.; Prosperi, S.; Gobetto, R.; Chierotti, M. R. From unexpected reactions to a new family of ionic co-crystals: the case of barbituric acid with alkali bromides and caesium iodide Chem. Commun. 2010, 46 (41) 7715-7
41. Bruker APEX2, version 2008.1-0; Bruker AXS Inc.: Madison, WI, 2008.
42. SAINT, V6.28A; Data Reduction Software; Bruker AXS Inc.: Madison, WI, 2001.
43. Sheldrick, G. M. SADABS. Program for Empirical Absorption Correction; University of Göttingen: Göttingen, Germany, 1996.
44. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. OLEX2: A complete structure solution, refinement and analysis program J. Appl. Crystallogr. 2009, 42, 339-341
45. Farrugia, L. J. WinGX suite for small-molecule single-crystal crystallography J. Appl. Cryst. 1999, 32, 837-838 (Pubitemid 129794704)
46. Sheldrick, G. M. SHELXL-97. Program for the Refinement of Crystal; University of Göttingen: Göttingen, Germany, 1997.
47. Sheldrick, G. M. A short history of SHELX Acta Crystallogr. 2008, A64, 112-122
48. Sheldrick, G. M. Phase annealing in SHELX-90: Direct methods for larger structures Acta Crystallogr. 1990, A46, 467-473
49. Rybakowski, J. K.; Suwalska, A.; Skibinska, M.; Dmitrzak-Weglarz, M.; Leszczynska-Rodziewicz, A.; Hauser, J. Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes Am. J. Med. Genet., Part B 2007, 144B (6) 820-823 (Pubitemid 47417214)
50. Kim, J. S.; Chang, M. Y.; Yu, I. T.; Kim, J. H.; Lee, S. H.; Lee, Y. S.; Son, H. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo J. Neurochem. 2004, 89 (2) 324-236
51. Stolk, P.; Souverein, P. C.; Wilting, I.; Leufkens, H. G.; Klein, D. F.; Rapoport, S. I.; Heerdink, E. R. Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder Prostaglandins, Leukotrienes Essent. Fatty Acids 2010, 82 (1) 9-14
52. Rao, J. S.; Harry, G. J.; Rapoport, S. I.; Kim, H. W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients Mol. Psychiatry 2010, 15 (4) 384-392
53. Serhan, C. N.; Hong, S.; Gronert, K.; Colgan, S. P.; Devchand, P. R.; Mirick, G.; Moussignac, R. L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals J. Exp. Med. 2002, 196 (8) 1025-1037 (Pubitemid 35231761)
54. Basselin, M.; Kim, H. W.; Chen, M.; Ma, K.; Rapoport, S. I.; Murphy, R. C.; Farias, S. E. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation J. Lipid Res. 2010, 51 (5) 1049-1056
55. Basselin, M.; Villacreses, N. E.; Lee, H. J.; Bell, J. M.; Rapoport, S. I. Chronic lithium administration attenuates up-regulated brain arachidonic acid metabolism in a rat model of neuroinflammation J. Neurochem. 2007, 102 (3) 761-772 (Pubitemid 47057299)
56. Yu, F.; Wang, Z.; Tchantchou, F.; Chiu, C. T.; Zhang, Y.; Chuang, D. M. Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury J. Neurotrauma 2012, 29 (2) 362-374
57. Maksimovich, Ia. B.; Kresiun, V. I.; Ariaev, V. L. Effectiveness of lithium nicotinate in the treatment of experimental alcoholism Byull. Eksp. Biol. Med. 1983, 96 (8) 35-37
58. Kresyn, V. I.; Aryaev, V. L.; Kostev, F. I. Litonit: evaluation of clinical effectiveness Alcohol Alcohol. 1993, 28 (3) 333-337 (Pubitemid 23198662)
59. Kostev, F. I. Effect of Litonit and teturam on the course of biochemical processes in infectious inflammatory lesions of the kidneys in alcoholized animals Byull. Eksp. Biol. Med. 1985, 99 (6) 661-663 (Pubitemid 15234026)
60. Kresiun, V. I. Stress-protective properties of lithium nicotinate-a new derivative of nicotinic acid Byull. Eksp. Biol. Med. 1984, 97 (3) 312-315
61. Aksel'rod, L. B.; Kresiun, V. I.; Moiseev, I. N.; Sukolovskaia, D. M.; Kravchenko, L. S. Functional changes in the myocardium and the reticular formation of the medulla oblongata in cardiogenic stress as affected by pharmacological correction with Litonit Byull. Eksp. Biol. Med. 1988, 105 (4) 453-455
62. Kasteleijn-Nolstlt Trenite, D. G.; Edelbroek, P. M. Antiepileptic drug treatment in the nineties in The Netherlands Pharm. World Sci. 1997, 19 (2) 60-69 (Pubitemid 27209928)
63. Lugassy, D.; Nelson, L. Case files of the medical toxicology fellowship at the New York City poison control: bromism: forgotten, but not gone J. Med. Toxicol. 2009, 5 (3) 151-157
64. Frances, C.; Hoizey, G.; Lamiable, D.; Millart, H.; Trenque, T. Bromism from daily over intake of bromide salt J. Toxicol., Clin. Toxicol. 2003, 41 (2) 181-183 (Pubitemid 36520469)
65. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12 (3) 413-420
66. Lippmann, S.; Evans, R. A comparison of three types of lithium release preparations Hosp. Community Psychiatry 1983, 34 (2) 113-114 (Pubitemid 13111605)
67. Cooper, T. B.; Simpson, G. M.; Lee, J. H.; Bergner, P. E. Evaluation of a slow-release lithium carbonate formulation Am. J. Psychiatry 1978, 135 (8) 917-922 (Pubitemid 8378231)
68. Emami, J.; Tavakoli, N.; Movahedian, A. Formulation of sustained-release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation J. Pharm. Pharm. Sci. 2004, 7 (3) 338-344 (Pubitemid 41528884)
69. Ciftci, K.; Capan, Y.; Ozturk, O.; Hincal, A. A. Formulation and in vitro-in vivo evaluation of sustained-release lithium carbonate tablets Pharm. Res. 1990, 7 (4) 359-363 (Pubitemid 20266589)